|
|
|
31.03.26 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 31 March 2026 — During March 2026, 54,450 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,450.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,934,734 corresponding to 59,934,734 votes. As of 31 March 2026, the total number of shares in Camurus amounts to 59,989,184 corresponding to 59,989,184...
|
|
|
27.02.26 - 15:30
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 27 February 2026 — During February 2026, 54,550 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,550.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,880,184 corresponding to 59,880,184 votes. As of 27 February 2026, the total number of shares in Camurus amounts to 59,934,734 corresponding to...
|
|
|
|
|
17.02.26 - 08:00
|
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer (Cision)
|
|
|
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive management team, effective 23 March, 2026.
Jane brings more than 20 years of experience from senior positions at Novo Nordisk and AstraZeneca within Business and Corporate Development, with a strong track record of driving strategic licensing and M&A transactions, integration processes and alliance management. Most recently, she had the position as Corporate VP in Global Business...
|
|
|
|
|
|
|
|
|
|
|
12.02.26 - 07:00
|
Camurus′ Full Year Report 2025 (Cision)
|
|
|
“Fourth quarter performance paves the way for a productive 2026”
Fourth quarter and full year summary
October - December
· Total revenues decreased 16% (3% at CER[1]) to SEK 464 (553) million, impacted by a one-time repurchase of inventory of 93 MSEK due to a change of the UK distribution model at the end of the period
· Product sales decreased 27% (17% at CER[1]) to SEK 342 (469) million
· Royalties increased 47% (82% at CER[1]) to SEK 122 (83) million
· Profit before tax decreased 32% (0% at CER[1]) to SEK 127 (186) million
· The cash position at the end of the...
|
|
|
22.01.26 - 09:54
|
AKTIONÄR-Tipp Camurus: "Top-Pick" – mit Eli Lilly in neue Dimensionen (Der Aktionaer)
|
|
|
Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue Rekorde zu. DER AKTIONÄR erklärt, was jetzt für einen Kauf der Anteile der Skandinavier spricht, die unter anderem mit dem Pharma-Riesen Eli Lilly zusammenarbeiten....
|
|
|
|
|
30.12.25 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 30 December 2025 — During December 2025, 7,350 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 7,350.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,872,834 corresponding to 59,872,834 votes. As of 30 December 2025, the total number of shares in Camurus amounts to 59,880,184 corresponding to...
|
|
|
16.12.25 - 11:57
|
Gubra und Camurus: 2 AKTIONÄR-Tipps, ein Ziel – die Hintergründe! (Der Aktionaer)
|
|
|
Die beiden skandinavischen Biotech-Gesellschaften Camurus und Gubra bündeln ihr Know-how. Eine aufgesetzte exklusive Kooperations- und Lizenzvereinbarung dient dem Ziel die Entwicklung einer langwirksamen Therapieoption für die Behandlung von Hypoparathyreoidismus, einer Unterfunktion der Nebenschilddrüsen....
|
|
|
16.12.25 - 11:30
|
Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism (Cision)
|
|
|
Lund, Sweden and Hørsholm, Denmark — 16 December 2025 — Camurus (NASDAQ STO: CAMX) and Gubra, a company specialized in peptide-based drug discovery, today announced that the companies have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.
This research and development collaboration will combine Gubra's parathyroid hormone (PTH) analogue, developed using the company's proprietary streaMLine peptide discovery platform, with Camurus' FluidCrystal[®] drug delivery technology to enable...
|
|
|
28.11.25 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 28 November 2025 — During November 2025, 24,200 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 24,200.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,848,634 corresponding to 59,848,634 votes. As of 28 November 2025, the total number of shares in Camurus amounts to 59,872,834 corresponding to...
|
|
|
13.11.25 - 07:00
|
Camurus′ Nomination Committee appointed for the Annual General Meeting 2026 (Cision)
|
|
|
Lund, Sweden — 13 November 2025 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2026 consists of the following persons, who together represent about 40 percent of the total number of shares and votes in Camurus based on the last known shareholder information:
· Per Sandberg, appointed by Sandberg Development AB,
· Arne Lööw, appointed by Fjärde AP-fonden,
· Oscar Bergman, appointed by Swedbank Robur Fonder, and
· Per Olof Wallström, Chairman of the Board of Camurus
The Nomination Committee's proposals will be presented in the...
|
|
|
12.11.25 - 10:02
|
Camurus to present at Jefferies London Healthcare Conference (Cision)
|
|
|
Lund, Sweden — 12 November 2025 — Camurus (NASDAQ STO: CAMX) will attend the Jefferies Global Healthcare Conference in London 17–20 November. President and CEO Fredrik Tiberg will present on 18 November at 9.30 am CET, giving an update on the company's recent developments.
A webcast of the presentation can be accessed via:
https://wsw.com/webcast/jeff332/register.aspx?conf=jeff332&page=camx&url=https://wsw.com/webcast/jeff332/camx/1839403
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com (mir@camurus.com)
About...
|
|
|
10.11.25 - 10:01
|
AKTIONÄR-Tipp Camurus: Gamechanger im Adipositas-Markt? Kurssprung! (Der Aktionaer)
|
|
|
Der Adipositas-Markt zählt innerhalb der Biopharma-Branche weiterhin zu den heißesten Bereichen – nicht zuletzt durch den Bieterkampf zwischen Pfizer und Novo Nordisk um Metsera. Unlängst verschiebt sich der Fokus bei der Entwicklung auf weitere Parameter neben der absoluten Gewichtsreduktion in einem bestimmten Zeitraum....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
